Moonlake Immunotherapeutics
A clinical-stage biopharmaceutical company based in Switzerland that develops immunotherapies. The grounding search tool was unavailable during this attempt, so no verified facts could be retrieved; please retry the request to obtain a properly sourced description.
| Holder | Schedule | % of class | Shares | Filed |
|---|---|---|---|---|
| Deep Track Capital, LP | 13G/APassive | 9.74% | 8.00M | Aug 14, 2026 |
| Deep Track Biotechnology Master Fund, Ltd. | 13G/APassive | 9.74% | 8.00M | Aug 14, 2026 |
| David Kroin | 13G/APassive | 9.74% | 8.00M | Aug 14, 2026 |
| T. Rowe Price Investment Management, Inc. | 13GPassive | 5.3% | 4.28M | Aug 14, 2026 |
| Cormorant Asset Management, LP | 13G/APassive | 4.35% | 3.21M | Aug 14, 2026 |
| Bihua Chen | 13G/APassive | 4.35% | 3.21M | Aug 14, 2026 |
| BVF PARTNERS L P/IL | 13D/AActivist | 19.7% | 16.00M | Jun 29, 2026 |
| BVF INC/IL | 13D/AActivist | 19.7% | 16.00M | Jun 29, 2026 |
| LAMPERT MARK N | 13D/AActivist | 19.7% | 16.00M | Jun 29, 2026 |
| BVF GP HOLDINGS LLC | 13D/AActivist | 18.4% | 14.90M | Jun 29, 2026 |